RxDoctor Payments Data

Dara Aisner, MD

Molecular Genetic Pathology · Aurora, CONPI 1538321831

Payments from drug & device makers

$23,228in general payments, 2019–2025

Across 22 payments — averaging $1055.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • Bayer$3K
  • Blueprint Medicines Corporation$3K
  • Sanofi$2K
  • AbbVie$2K
  • plus $6K from 3 others

What the payments were for

  • Consulting fees$14,59363%
  • Speaking & faculty fees$7,07330%
  • Travel & lodging$1,1905%
  • Food & beverage$3712%

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few molecular genetic pathology providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$12,525
Medicare patients
126
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other molecular genetic pathology in Aurora

Where these figures come from

Is this you, or does something look wrong? →